Remus Pharmaceuticals Ltd Q2 FY26 – ₹400 Cr Sales, ₹22 Cr PAT, 46% YoY Revenue Surge: The Gujarati Pharma Exporter That Treats Borders Like Mild Suggestions
1. At a Glance
Welcome to the desi export factory that ships more molecules than a Chemistry lab on steroids — Remus Pharmaceuticals Ltd (RPL). Incorporated in 2015 and now rocking a ₹771 crore market cap, this Gujarat-based pharma trader seems to have found its sweet spot in the API–formulation–consultancy triangle.
At ₹654 per share (Nov 25, 2025), RPL looks like it’s suffering from a post-bonus hangover, down 46% over the past year and 30% in the last 3 months — but let’s not forget, sales have exploded to ₹748 crore (TTM), up 63%, while PAT stands strong at ₹42 crore, up 20%. The company barely carries any debt (₹16 crore, D/E = 0.05), flaunts a ROCE of 19.6%, and runs a lean business model — no factories, just smarts, contracts, and global shipping routes.
So, if you ever thought you could build a ₹700 crore business just by managing WhatsApp groups of contract manufacturers, RPL might be your next role model.
2. Introduction
If you blinked during 2023–25, you probably missed one of the most rapid pharma upstarts in SME history. Remus Pharma began as a humble exporter, then started playing in Critical Care, Cardiology, and Diabetology, and now basically treats global borders as optional. With clients spread across 20+ countries — from Bhutan to Venezuela — this company’s sales map looks like an overachieving travel blogger’s itinerary.
They don’t manufacture a single pill themselves. Instead, Remus gets 30 loan-licensed facilities across Gujarat to do the heavy lifting. The result? A margin-light but asset-light model that lets them focus on marketing and regulatory paperwork while others sweat in the factories.
While most SMEs fight for domestic shelf space, Remus exports 98% of its goods. Domestic sales? Just 2%. Clearly, they’ve realized there’s less red tape in Latin America than in a typical Indian state tender.
So what’s their secret? A mix of complex generics, off-patent formulations, and a distributor army of ~197 partners globally. Oh, and the usual desi tricks — family control, zero pledges, and the occasional bonus share party (3:1 in FY24, 1:1 in FY25).
3. Business Model – WTF Do They Even Do?
Alright, let’s simplify this. Remus is not a manufacturer, not a hospital supplier, and not an R&D powerhouse. It’s a pharma middleman — but an elite one. Think of them as the Amazon of formulations: they find what works, get it made under license, package it, and ship it to 20 countries.
Their business runs across three main verticals:
Finished Formulations (≈86% of revenue): Tablets, capsules, creams, injections — basically, everything your chemist hides behind the counter.
API Trading (≈10%): The raw ingredients of pharma, the cocaine of the legal drug world.
Technical Consultancy (≈4%): Dossier prep, regulatory documents, and reports — aka, paperwork for cash.
The genius here? Zero plant headaches, zero CAPEX, and 30 contract manufacturers in Gujarat doing the grunt work. They manage licensing, branding, and export compliance — and laugh their way to the bank.
Their clientele includes multinational distributors, regional partners, hospitals, and clinics across Asia, Africa, and Latin America. When your export geography list includes Madagascar and Trinidad, you know you’re hustling globally.
So in short: they don’t make drugs — they make money from making others make drugs.
At CMP ₹654, P/E = 22x annualised EPS, slightly below the sector median (≈31x).
Commentary: Revenue up 47% YoY, profit up 16%, but OPM slid from 14% to 7%. Why? Simple — margin compression from aggressive expansion and pricing competition in exports. The operating model is strong, but clearly the air miles are eating into the margins.
5. Valuation Discussion – Fair Value Range Only
Let’s crunch a few desi valuation numbers:
A. P/E Based Range
Annualised EPS = ₹29.7
Industry P/E = 31x
RPL current P/E = 22x
→ Fair Value = ₹29.7 × (22–31) = ₹653 – ₹920 per share
So at ₹654, it’s exactly hugging the lower bound — fair,
